Vaccine Sputnik Light — single dose vaccine, authorized for use in Russia. Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.
The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021.
An efficacy level of almost 80% is higher than that of many two-dose vaccines.
Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.
Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:
- Sputnik Light can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination;
- The Sputnik Light vaccine elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization;
- Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day;
- The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization;
- No serious adverse events were registered after vaccination with Sputnik Light.
Sputnik Light (Russian: «Спутник Лайт», romanized: Sputnik Layt or Lajt) is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It actually consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version, with an effectiveness of 79.4%, would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly.